Multiparticulate and matrix-based strategies for modified Melatonin release

Chhanda Kapadia – Group Director-Technical services, IMCD Group; Nishant Nirale – Manager - Technical Application, IMCD India; Simon Roberts – Controlled Release Manager - EMEA, IMCD UK

Poster Presenter(s)

Roza Markovski, n/a

Laboratory Manager
IMCD Deutschland GmbH
Cologne, Nordrhein-Westfalen, Germany

Introduction:

Melatonin (MT) is a nocturnally secreted pineal gland hormone with pleiotropic chronobiological effects (1). Orally administered MT, available in immediate-release dosage forms, has poor and variable bioavailability. Immediate release is effective for delayed sleep onset, while modified release systems are designed to provide better control of plasma profiles. Various formulation approaches, including multilayer tablets and multiple-dose systems, often use different modified release polymers (2). Pulsatile or delayed-release formulations that deliver an initial dose for sleep induction followed by delayed release, may better mimic endogenous melatonin secretion (3).

Learning Objectives:

Understand the principles of pulsatile and sustained MT release systems to mimic physiological circadian rhythm.
Assess effects of HPMC concentration, viscosity and substitution level on MT release from hydrophilic matrices.
Generate data to improve the scale-up process for melatonin matrix-based controlled release dosage forms.